The Dualase® genome editing platform is set to be presented by Specific Biologics Inc. at the upcoming 28th Annual ASGCT Meeting. This ground-breaking innovation presents preclinical data on its potential to treat repeat expansion disorders — a group of severe genetic conditions including ALS, Huntington’s disease, Fragile X syndrome, and myotonic dystrophy.
The Dualase® genome editing platform differs from existing therapies, which usually focus on managing symptoms, by attempting to address the root cause. Specific Biologics Inc.'s solution precisely excises abnormally expanded DNA repeats while preserving a non-pathogenic sequence length. This approach offers the possibility of a one-time, curative treatment.
The genome editing platform's two-site targeting mechanism allows for highly specific editing. Its compact design, on the other hand, enables efficient delivery via single AAV vectors, even to challenging tissues like the central nervous system.
Genome Editing Platforms
Specific Biologics Will Showcase Its Dualase® Genome Editing Platform
Trend Themes
-
Precision Genome Editing — The emergence of precision genome editing technologies offers the potential to directly address genetic root causes of disorders rather than merely treating symptoms.
-
Single-treatment Genetic Therapies — Innovative genome editing platforms are paving the way for the development of single-treatment genetic therapies that aim to provide long-term curative outcomes.
-
Efficient Gene Delivery Systems — Advancements in gene delivery systems, like compact AAV vectors, are enabling targeted therapies to reach traditionally challenging tissues with greater precision and efficacy.
Industry Implications
-
Biotechnology — The biotechnology industry is poised to benefit from breakthroughs in genome editing platforms that promise transformative treatments for genetic disorders.
-
Gene Therapy — Gene therapy continues to experience growth with the introduction of novel genome editing solutions targeting the direct correction of genetic abnormalities.
-
Neurology — The neurology field is set to be revolutionized by genome editing technologies offering potential cures for genetic neurological conditions previously considered intractable.